Diagnostic accuracy of urinary survivin mRNA expression detected by RT‑PCR compared with urine cytology in 
the detection of bladder cancer: A meta‑analysis of diagnostic test accuracy in head‑to‑head studies

Fu,Liang; Zhang,Jiwang; Li,Ling; Yang,Yuxing; Yuan,Yongqiang

doi:10.3892/ol.2019.11227

Diagnostic accuracy of urinary survivin mRNA expression detected by RT‑PCR compared with urine cytology in the detection of bladder cancer: A meta‑analysis of diagnostic test accuracy in head‑to‑head studies

Authors:
- Liang Fu
- Jiwang Zhang
- Ling Li
- Yuxing Yang
- Yongqiang Yuan
View Affiliations

Affiliations: Clinical Laboratory, Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, P.R. China, Department of Pathology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumchi, Xinjiang 830001, P.R. China
Published online on: December 18, 2019 https://doi.org/10.3892/ol.2019.11227
Pages: 1165-1174
Copyright: © Fu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Survivin is a promising marker for the diagnosis of bladder cancer. The accuracy and clinical value of urinary survivin mRNA expression were compared with urine cytology, which is the standard diagnostic method for bladder cancer. Scientific databases, including PubMed, Web of Science, Cochrane Library and China National Knowledge Infrastructure, were searched in order to find studies that examined urinary survivin mRNA expression and urine cytology in the diagnosis of bladder cancer. Quality assessment was performed using the Quality Assessment of Diagnostic Accuracy Studies 2 tool in Revman 5.3 and data analysis was conducted using Stata/MP. The I2 statistic was used to evaluate heterogeneity and Deeks' funnel plot was generated to assess the possibility of publication bias. A total of 15 studies that evaluated a total of 1,624 patients were included in the present meta‑analysis. The pooled sensitivity and specificity values for the detection of urinary survivin mRNA expression in the diagnosis of bladder cancer were 0.86 [95% confidence interval (CI), 0.81‑0.90] and 0.95 (95% CI, 0.93‑0.96), respectively. Regarding urine cytology, the pooled sensitivity and specificity values were 0.42 (95% CI, 0.36‑0.48) and 1.00 (95% CI, 0.98‑1.00), respectively. Furthermore, the differences in pooled sensitivity were statistically significant in the diagnosis of grade 1 and 2 bladder tumors. Summary receiver operating characteristic curve values for urinary survivin mRNA expression and urine cytology were 0.95 (95% CI, 0.93‑0.97) and 0.86 (95% CI, 0.83‑0.89), respectively. Urinary survivin mRNA expression was also more accurate compared with other diagnostic indicators, including positive likelihood ratios, negative likelihood ratios, diagnostic odds ratios and Youden's index. Compared with traditional urine cytology, urinary survivin mRNA detection using reverse transcription‑PCR was identified to be more effective in the diagnosis of early bladder cancer.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Witjes JA and Hendricksen K: Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: A critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol. 53:45–52. 2008. View Article : Google Scholar : PubMed/NCBI
3	Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, et al: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013. Eur Urol. 64:639–653. 2013. View Article : Google Scholar : PubMed/NCBI
4	Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, Shariat SF, Xylinas E, Schmitz-Dräger BJ, Lotan Y, et al: ICUD-EAU International Consultation on bladder cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol. 63:4–15. 2013. View Article : Google Scholar : PubMed/NCBI
5	Burke DM, Shackley DC and O'Reilly PH: The community-based morbidity of flexible cystoscopy. BJU Int. 89:347–349. 2002. View Article : Google Scholar : PubMed/NCBI
6	Biardeau X, Lam O, Ba V, Campeau L and Corcos J: Prospective evaluation of anxiety, pain, and embarrassment associated with cystoscopy and urodynamic testing in clinical practice. Can Urol Assoc J. 11:104–110. 2017. View Article : Google Scholar : PubMed/NCBI
7	Raitanen MP, Leppilahti M, Tuhkanen K, Forssel T, Nylund P and Tammela T; FinnBladder Group, : Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer. Ann Chir Gynaecol. 90:261–265. 2001.PubMed/NCBI
8	Lotan Y and Roehrborn CG: Sensitivity and specificity of commonly available bladder tumour markers versus cytology: Results of a comprehensive literature review and meta-analyses. Urology. 61:109–118. 2003. View Article : Google Scholar : PubMed/NCBI
9	Oeyen E, Hoekx L, De Wachter S, Baldewijns M, Ameye F and Mertens I: Bladder cancer diagnosis and follow-up: The current status and possible role of extracellular vesicles. Int J Mol Sci. 20(pii): E8212019. View Article : Google Scholar : PubMed/NCBI
10	Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP III, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, et al: Bladder tumour markers beyond cytology: International consensus panel on bladder tumour markers. Urology. 66 (6 Suppl 1):35–63. 2005. View Article : Google Scholar : PubMed/NCBI
11	D'Costa JJ, Goldsmith JC, Wilson JS, Bryan RT and Ward DG: A systematic review of the diagnostic and prognostic value of urinary protein biomarkers in urothelial bladder cancer. Bladder Cancer. 2:301–317. 2016. View Article : Google Scholar : PubMed/NCBI
12	Garg H, Suri P, Gupta JC, Talwar GP and Dubey S: Survivin: A unique target for tumour therapy. Cancer Cell Int. 16:492016. View Article : Google Scholar : PubMed/NCBI
13	Jacob NK, Cooley JV, Shirai K and Chakravarti A: Survivin splice variants are not essential for mitotic progression or inhibition of apoptosis induced by doxorubicin and radiation. Onco Targets Ther. 5:7–20. 2012. View Article : Google Scholar : PubMed/NCBI
14	Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
15	Swana HS, Grossman D, Anthony JN, Weiss RM and Altieri DC: Tumour content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med. 341:452–453. 1999. View Article : Google Scholar : PubMed/NCBI
16	Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM and Altieri DC: Urine detection of survivin and diagnosis of bladder cancer. JAMA. 285:324–328. 2001. View Article : Google Scholar : PubMed/NCBI
17	Shariat SF, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC and Lerner SP: Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol. 171:626–630. 2004. View Article : Google Scholar : PubMed/NCBI
18	Liang Z, Xin R, Yu Y, Wang R, Wang C and Liu X: Diagnostic value of urinary survivin as a biomarker for bladder cancer: A systematic review and meta-analysis of published studies. World J Urol. 36:1373–1381. 2018. View Article : Google Scholar : PubMed/NCBI
19	Weikert S, Christoph F, Schrader M, Krause H, Miller K and Muller M: Quantitative analysis of survivin mRNA expression in urine and tumour tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer. 116:100–104. 2005. View Article : Google Scholar : PubMed/NCBI
20	Pu XY, Wang ZP, Chen YR, Wang XH, Wu YL and Wang HP: The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine. J Cancer Res Clin Oncol. 134:659–665. 2008. View Article : Google Scholar : PubMed/NCBI
21	Eissa S, Badr S, Elhamid SA, Helmy AS, Nour M and Esmat M: The value of combined use of survivin mRNA and matrix metalloproteinase 2 and 9 for bladder cancer detection in voided urine. Dis Markers. 34:57–62. 2013. View Article : Google Scholar : PubMed/NCBI
22	Moher D, Liberati A, Tetzlaff J, Altman DG and Group P: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 6:e10000972009. View Article : Google Scholar : PubMed/NCBI
23	Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA and Bossuyt PM; QUADAS-2 Group, : QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 155:529–536. 2011. View Article : Google Scholar : PubMed/NCBI
24	Skupski DW, Rosenberg CR and Eglinton GS: Intrapartum fetal stimulation tests: A meta-analysis. Obstet Gynecol. 99:129–134. 2002. View Article : Google Scholar : PubMed/NCBI
25	Deeks JJ, Macaskill P and Irwig L: The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 58:882–893. 2005. View Article : Google Scholar : PubMed/NCBI
26	Glas AS, Lijmer JG, Prins MH, Bonsel GJ and Bossuyt PM: The diagnostic odds ratio: A single indicator of test performance. J Clin Epidemiol. 56:1129–1135. 2003. View Article : Google Scholar : PubMed/NCBI
27	Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM and Zwinderman AH: Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 58:982–990. 2005. View Article : Google Scholar : PubMed/NCBI
28	Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
29	Ye X, Xiao H, Chen B and Zhang S: Accuracy of lung ultrasonography versus chest radiography for the diagnosis of adult community-acquired pneumonia: Review of the literature and meta-analysis. PLoS One. 10:e01300662015. View Article : Google Scholar : PubMed/NCBI
30	Al-Maghrebi M, Kehinde EO, Kapila K and Anim JT: Urinary survivin mRNA expression and urinary nuclear matrix protein 22 BladderChek^® and urine cytology in the detection of transitional cell carcinoma of the bladder. Med Princ Pract. 21:295–297. 2012. View Article : Google Scholar : PubMed/NCBI
31	Pina-Cabral L, Santos L, Mesquita B, Amaro T, Magalhães S and Criado B: Detection of survivin mRNA in urine of patients with superficial urothelial cell carcinomas. Clin Transl Oncol. 9:731–736. 2007. View Article : Google Scholar : PubMed/NCBI
32	Eissa S, Swellam M, Shehata H, El-Khouly IM, El-Zayat T and El-Ahmady O: Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer. J Urol. 183:493–498. 2010. View Article : Google Scholar : PubMed/NCBI
33	Eissa S, Shabayek MI, Ismail MF, El-Allawy RM and Hamdy MA: Diagnostic evaluation of apoptosis inhibitory gene and tissue inhibitor matrix metalloproteinase-2 in patients with bladder cancer. IUBMB Life. 62:394–399. 2010.PubMed/NCBI
34	Jiang G, Zhang JH, Jian RJ and Chen ZD: Clinical significance of survivin mRNA level and hyaluronic acid level detection of patients suffered from bladder transitional cell carcinomas. Sichuan Med J. 11:1162–1164. 2006.
35	Lin Y, Han ZH and Liu T: The clinical significance of urinary survivin mRNA detection for bladder transitional cell carcinoma. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine. 17:21–22. 2007.
36	Liu JG, Yang JY and Wei W: The value of combined detection of urinary cell keratin 19, nuclear matrix protein 22 and survivin in the early diagnosis of bladder cancer. China Foreign Medical Treatment. 28:1682009.
37	Pu XY, Wang ZP, Chen YR, Wu YL, Wang HP and Wang XH: Combined use of uirnary bladder cancer antigen, hyaluronic aeid and survivin for the detection of bladder cancer. Chin J Urol. 27:970–973. 2008.
38	Wan JH, Jin FS, Xiang D, Hu B and Gao F: Value of cytokeratin 20 and survivin in the diagnosis of bladder tumour. J Clin Res. 25:428–431. 2008.
39	Wang L, Zeng FQ, Liao GY and Chen FM: Detection of survivin in exfoliated urothelial cells of bladder cancer. J Clin Urol. 19:489–490. 2004.
40	Wang ZH, Hu ZQ, Ye Q, Ye ZQ, Cai D, Yang N, Liu H, Zhuang QY, Yang WM, et al: Clinical application of survivin detection in urothelial cells of patients with transitional cell carcinoma of bladder. Chin J Exper Surg. 23:959–961. 2006.
41	Zhang WX, Zhen S and Zhen T: Diagnosis of bladder cancer by detection of survivin and minichromosome maitence5 protein in urine sediment. Chin J Urol. 26:233–236. 2005.
42	Nicolazzo C, Busetto GM, Del Giudice F, Sperduti I, Giannarelli D, Gradilone A, Gazzaniga P, de Berardinis E and Raimondi C: The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC). J Cancer Res Clin Oncol. 143:1971–1976. 2017. View Article : Google Scholar : PubMed/NCBI
43	Gogalic S, Sauer U, Doppler S and Preininger C: Bladder cancer biomarker array to detect aberrant levels of proteins in urine. Analyst. 140:724–735. 2015. View Article : Google Scholar : PubMed/NCBI
44	Herr HW: The risk of urinary tract infection after flexible cystoscopy in patients with bladder tumor who did not receive prophylactic antibiotics. J Urol. 193:548–551. 2015. View Article : Google Scholar : PubMed/NCBI
45	Eissa S, Kassim SK, Labib RA, El-Khouly IM, Ghaffer TM, Sadek M, Razek OA and El-Ahmady O: Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs. Cancer. 103:1356–1362. 2005. View Article : Google Scholar : PubMed/NCBI
46	Chang Y, Xu J and Zhang Q: Microplate magnetic chemiluminescence immunoassay for detecting urinary survivin in bladder cancer. Oncol Lett. 14:4043–4052. 2017. View Article : Google Scholar : PubMed/NCBI
47	Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 22:8581–8589. 2003. View Article : Google Scholar : PubMed/NCBI
48	Kitsukawa S, Aoyagi T, Noda K, Ito T, Yamamoto Y, Hosoda S, Otsuru N and Matsumoto T: Quantitative analysis of survivin mRNA expression in bladder transitional cell carcinomas. Hinyokika Kiyo. 54:101–106. 2008.PubMed/NCBI
49	Moussa O, Abol-Enein H, Bissada NK, Keane T, Ghoneim MA and Watson DK: Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. J Urol. 175:2312–2316. 2006. View Article : Google Scholar : PubMed/NCBI
50	Pormohammad A, Riahi SM, Nasiri MJ, Fallah F, Aghazadeh M, Doustdar F and Pouriran R: Diagnostic test accuracy of adenosine deaminase for tuberculous meningitis: A systematic review and meta-analysis. J Infect. 74:545–554. 2017. View Article : Google Scholar : PubMed/NCBI